Patents by Inventor Terri Lynn Davis
Terri Lynn Davis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9273113Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.Type: GrantFiled: August 13, 2012Date of Patent: March 1, 2016Assignee: GENENTECH, INC.Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
-
Publication number: 20130178418Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.Type: ApplicationFiled: August 13, 2012Publication date: July 11, 2013Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
-
Patent number: 8273353Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.Type: GrantFiled: April 28, 2011Date of Patent: September 25, 2012Assignee: Genentech, Inc.Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
-
Patent number: 8268591Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.Type: GrantFiled: April 28, 2011Date of Patent: September 18, 2012Assignee: Genentech, Inc.Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
-
Patent number: 8268313Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.Type: GrantFiled: April 28, 2011Date of Patent: September 18, 2012Assignee: Genentech, Inc.Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
-
Publication number: 20110300577Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.Type: ApplicationFiled: April 28, 2011Publication date: December 8, 2011Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
-
Publication number: 20110300578Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.Type: ApplicationFiled: April 28, 2011Publication date: December 8, 2011Inventors: Terri Lynn Davis-Smyth, Helen Heifel Chen, Leonard Presta, Napoleone Ferrara
-
Publication number: 20110301338Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.Type: ApplicationFiled: April 28, 2011Publication date: December 8, 2011Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
-
Publication number: 20110301337Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.Type: ApplicationFiled: April 28, 2011Publication date: December 8, 2011Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
-
Publication number: 20110301339Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.Type: ApplicationFiled: April 28, 2011Publication date: December 8, 2011Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
-
Patent number: 8065225Abstract: A computer-implemented method for processing an application for a mortgage loan, such that the mortgage loan is configured to include a set of financial lending requirements and further include certain financial lending risks associated with financing the mortgage loan. The steps of the method include receiving the mortgage loan application, processing the mortgage loan application through an electronic database, applying the set of financial lending requirements to the mortgage loan application, generating a listing of at least one eligible lender or loan product based on the application of the financial lending requirements to the mortgage loan application, and submitting the mortgage loan application to the eligible lender, the mortgage loan being configured such that the financial lending risks are configured to be absorbed by a secondary mortgage market investor.Type: GrantFiled: September 18, 2007Date of Patent: November 22, 2011Assignee: Fannie MaeInventors: Harold Lewis, Jr., Tracey G. Amos, Eric Ronald Anders, Nitirwork Armstrong, Sidney Vince Credle, Jr., Terri Lynn Davis, Thomas L. King, Gregory Joseph Phillips, Robert John Sahadi
-
Publication number: 20110213130Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.Type: ApplicationFiled: April 28, 2011Publication date: September 1, 2011Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
-
Patent number: 7771721Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and anglogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.Type: GrantFiled: April 17, 2008Date of Patent: August 10, 2010Assignee: Genentech, Inc.Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
-
Publication number: 20090234103Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.Type: ApplicationFiled: April 17, 2008Publication date: September 17, 2009Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
-
Publication number: 20090010933Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and anglogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.Type: ApplicationFiled: April 17, 2008Publication date: January 8, 2009Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
-
Patent number: 6897294Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.Type: GrantFiled: March 20, 2002Date of Patent: May 24, 2005Assignee: Genentech, Inc.Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
-
Publication number: 20030092604Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.Type: ApplicationFiled: March 20, 2002Publication date: May 15, 2003Applicant: Genentech, Inc.Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
-
Patent number: 6383486Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.Type: GrantFiled: July 1, 1999Date of Patent: May 7, 2002Assignee: Genentech, Inc.Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
-
Patent number: 6100071Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.Type: GrantFiled: May 7, 1996Date of Patent: August 8, 2000Assignee: Genentech, Inc.Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
-
Patent number: 5952199Abstract: The present invention is directed to novel VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1, FLT4, and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.Type: GrantFiled: June 13, 1997Date of Patent: September 14, 1999Assignee: Genentech, Inc.Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara